On January 12, 2026, a new clinical investigation focusing on an advanced ostomy baseplate, identified as CP381, was announced as actively recruiting participants. This groundbreaking study aims to assess the performance and safety of this novel medical device designed for individuals with a stoma or ileostomy. Sponsored by Coloplast A/S, a global leader in ostomy care, the trial promises to deliver critical insights that could improve the quality of life for patients with ostomies.
In this article:
- What changed?
- What is CP381?
- Why should regulatory and clinical teams care?
- FAQ
- Conclusion
- Disclaimer
- Full announcement
What changed?
The clinical trial for the CP381 ostomy baseplate has started recruiting participants as of January 2026. This signifies a critical step in evaluating the device’s clinical performance under the regulatory and scientific scrutiny needed for medical device validation. Individuals living with a stoma or ileostomy are the core demographic, and the findings are expected to identify potential benefits such as enhanced comfort, longevity, and adhesion safety.
What is CP381?
CP381 is a newly developed medical device manufactured by Coloplast A/S, targeting people with a stoma or ileostomy. Baseplates are integral to ostomy care, as they secure ostomy pouches and ensure skin protection around the stoma site. The innovation in CP381 is expected to focus on improved adhesion, enhanced patient comfort, and reduced skin irritation.
Coloplast A/S is renowned for its commitment to advancing medical devices that address the everyday challenges of individuals with intimate healthcare needs. This trial underscores the company’s investment in research and development to ensure their products meet high safety and performance standards.
Why should regulatory and clinical teams care?
Regulatory and clinical teams play a significant role in facilitating innovation while ensuring compliance with medical device safety frameworks like the Medical Device Regulation (MDR) in Europe and FDA requirements in the United States. This trial offers an opportunity to observe how CP381 aligns with clinical and regulatory expectations. Insights gained from this trial may set precedents for evaluating future devices for ostomy management.
Transparent reporting of clinical results and compliance with post-market surveillance requirements will be critical for CP381’s eventual market introduction. In addition, participation data could influence regulatory benchmarks for similar devices under development.
FAQ
- Who is conducting this trial?
The trial is sponsored by Coloplast A/S, a leading company in ostomy and continence care. - What condition does the device target?
CP381 is intended for individuals with a stoma or ileostomy. - Is recruitment for participants open?
Yes, recruitment is currently active as of January 2026. - What distinguishes CP381 from existing products?
While specifics are undisclosed, the device reportedly focuses on improved adhesion, comfort, and skin protection. - Where can I find detailed regulatory or trial information?
You can find more details via the clinical trial record here.
Conclusion
The clinical investigation of CP381 represents a significant development in the field of ostomy care. Regulatory and clinical teams should track this trial closely as it may impact future device approvals, patient care practices, and innovation policies. For ongoing updates, visit the official clinical registration page.
Disclaimer
This article is for informational purposes only and does not constitute legal or clinical advice. Regulatory professionals should consult official guidelines for compliance measures.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07316530?term=medical+device